Membranoproliferative Glomerulonephritis and C3 Glomerulopathy in Children

Licht, Christoph; Vivarelli, Marina; Khursigara, Magdalena Riedl; Pickering, Matthew C.; Walker, Patrick D.

doi:10.1007/978-3-642-27843-3_29-2

Cited by 1 publication

(1 citation statement)

References 195 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, limited reports exist on the respective clinical courses of IC-MPGN and C3G, especially in pediatric patients, in whom MPGN is rare. There is also a lack of evidence-based standard treatment for patients with IC-MPGN and C3G, particularly in the pediatric population [7]. To elucidate the clinical characteristics of MPGN and to identify appropriate treatments, we reclassi ed types of MPGN based on kidney biopsy ndings in pediatric patients diagnosed with MPGN.…”

Section: Introductionmentioning

confidence: 99%

Clinical characteristics and long-term outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulopathy in Japanese children

Ueda,

Horinouchi,

Inoki

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Membranoproliferative glomerulonephritis (MPGN) can be divided into immune-complex MPGN (IC-MPGN) and C3 glomerulopathy (C3G), which include dense deposit disease (DDD) and C3 glomerulonephritis (C3GN), respectively. These conditions result from abnormalities in different complement pathways and may lead to different prognoses. However, there are limited studies describing the respective clinical courses. Methods In this study, Japanese pediatric patients diagnosed with MPGN based on kidney biopsies conducted between February 2002 and December 2022 were reclassified as having IC-MPGN or C3G (DDD or C3GN). We retrospectively analyzed the clinical characteristics and outcomes of these patients. Results Out of 25 patients with MPGN, three (12.0%) were diagnosed with DDD, 20 (80.0%) with C3GN, and two (8.0%) with IC-MPGN. There were 13 (65.0%) patients and one (33.3%) patient in remission after treatment for C3GN and DDD, respectively, and no patients with IC-MPGN achieved remission. The median follow-up period was 5.3 (2.5-8.9) years, and none of the patients in either group progressed to an estimated glomerular filtration rate < 15 ml/min/1.73m2. Patients with C3GN presenting mild to moderate proteinuria (n=8) received a renin-angiotensin system inhibitor (RAS-I) alone, and these patients exhibited a significant decrease in the urinary protein creatinine ratio and a notable increase in serum C3 levels at the last follow-up. Conclusions The majority of patients with MPGN were diagnosed with C3GN. The remission rate for C3GN was high, and no patients developed kidney failure, indicating favorable outcomes. Additionally, it was suggested that patients with mild pediatric C3GN could be treated with RAS-I alone.

show abstract

Section: Introductionmentioning

confidence: 99%